Role of plasma adiponectin on the HDL-cholesterol raising effect of atorvastatin in patients with type 2 diabetes^*

References

• Stamler JS, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors and 12-year cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993;16:434-44
   PubMed Web of Science ®Google Scholar
• Adlerberth AM, Rosengren A, Wilhelmsen L. Diabetes and long-term risk of mortality from coronary and other causes in middle-aged Swedish men. A general population study. Diabetes Care 1998;21:539-45
   PubMed Web of Science ®Google Scholar
• Lehto S, Ronnemaa T, Haffner SM, et al. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 1997;46:1354-9
   PubMed Web of Science ®Google Scholar
• Nishida M, Funahashi T, Shimomura I. Pathophysiological significance of adiponectin. Med Mol Morphol 2007;40:55-67
   PubMed Web of Science ®Google Scholar
• Sattar N, Wannamethee G, Sarwar N, et al. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 2006;114:623-9
   PubMed Web of Science ®Google Scholar
• Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20:1595-9
   PubMed Web of Science ®Google Scholar
• Laughlin GA, Barrett-Connor E, May S, et al. Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo study. Am J Epidemiol 2007;165:164-74
   PubMed Web of Science ®Google Scholar
• Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20:1595-9
   PubMed Web of Science ®Google Scholar
• Koenig W, Khuseyinova N, Baumert J, et al. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany. J Am Coll Cardiol 2006;48:1369-77
   PubMed Web of Science ®Google Scholar
• Cnop M, Havel PJ, Utzschneider KM, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003;46:459-69
   PubMed Web of Science ®Google Scholar
• Baratta R, Amato S, Degano C, et al. Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies. J Clin Endocrinol Metab 2004;89:2665-71
   PubMed Web of Science ®Google Scholar
• von Eynatten M, Schneider JG, Humpert PM, et al. Serum adiponectin levels are an independent predictor of the extent of coronary artery disease in men. J Am Coll Cardiol 2006;47:2124-6
   PubMed Web of Science ®Google Scholar
• Schneider JG, von Eynatten M, Schiekofer S, et al. Low plasma adiponectin levels are associated with increased hepatic lipase activity in vivo. Diabetes Care 2005;28:2181-6
   PubMed Web of Science ®Google Scholar
• von Eynatten M, Schneider JG, Humpert PM, et al. Decreased plasma lipoprotein lipase in hypoadiponectinemia: an association independent of systemic inflammation and insulin resistance. Diabetes Care 2004;27:2925-9
   PubMed Web of Science ®Google Scholar
• de Vries R, Wolffenbuttel BHR, Sluiter WJ, et al. Post-heparin plasma lipoprotein lipase, but not hepatic lipase activity, is related to plasma adiponectin in type 2 diabetic patients and healthy subjects. Clin Lab 2005;51:403-9
   PubMed Web of Science ®Google Scholar
• Verges B, Petit JM, Duvillard L, et al. Adiponectin is an important determinant of apoA-I catabolism. Arterioscler Thromb Vasc Biol 2006;26:1364-9
   PubMed Web of Science ®Google Scholar
• Berk-Planken II, Hoogerbrugge N, Jansen H, et al. DALI Study Group. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia - The DALI Study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care 2001;24:1335-41
   PubMed Web of Science ®Google Scholar
• Chu CS, Lee KT, Lee MY, et al. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Am J Cardiol 2006;97:646-50
   PubMed Web of Science ®Google Scholar
• Forst T, Pfutzner A, Lubben G, et al. Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk – the PIOSTAT Study. Metabolism 2007;56:491-6
   PubMed Web of Science ®Google Scholar
• Sugiyama S, Fukushima H, Kugiyama K, et al. Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease. Atherosclerosis 2007;194:E43-51
   PubMed Web of Science ®Google Scholar
• Sonmez A, Dogru T, Tasci I, et al. The effect of fluvastatin on plasma adiponectin levels in dyslipidaemia. Clin Endocrinol (Oxf) 2006;64:567-72
   PubMed Web of Science ®Google Scholar
• Blanco-Colio LM, Martin-Ventura JL, Gomez-Guerrero C, et al. Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk. Eur J Pharmacol 2008;586:259-65
   PubMed Web of Science ®Google Scholar
• Devaraj S, Siegel D, Jialal I. Simvastatin (40 mg/day), adiponectin levels, and insulin sensitivity in subjects with the metabolic syndrome. Am J Cardiol 2007;100:1397-9
   PubMed Web of Science ®Google Scholar
• Han SH, Quon MJ, Kim JA, et al. Adiponectin and cardiovascular disease: response to therapeutic interventions. J Am Coll Cardiol 2007;49:531-8
   PubMed Web of Science ®Google Scholar
• Supplement 1. American Diabetes Association: clinical practice recommendations 2000. Diabetes Care 2000;23( Suppl 1):S1-116
   PubMed Web of Science ®Google Scholar
• van Venrooij FV, Stolk RP, Banga JD, et al. Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes. Diabetes Care 2003;26:1216-23
   PubMed Web of Science ®Google Scholar
• de Vries R, Perton FG, Dallinga-Thie GM, et al. Plasma cholesteryl ester transfer is a determinant of intima-media thickness in type 2 diabetic and nondiabetic subjects: role of CETP and triglycerides. Diabetes 2005;54:3554-9
   PubMed Web of Science ®Google Scholar
• Jansen H, Hop W, van Tol A, et al. Hepatic lipase and lipoprotein lipase are not major determinants of the low density lipoprotein subclass pattern in human subjects with coronary heart disease. Atherosclerosis 1994;107:45-54
   PubMed Web of Science ®Google Scholar
• Lindsay RS, Funahashi T, Hanson RL, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002;360:57-8
   PubMed Web of Science ®Google Scholar
• Tschritter O, Fritsche A, Thamer C, et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 2003;52:239-43
   PubMed Web of Science ®Google Scholar
• Blumer RM, van der Crabben SN, Stegenga ME, et al. Hyperglycemia prevents the suppressive effect of hyperinsulinemia on plasma adiponectin levels in healthy humans. Am J Physiol Endocrinol Metab 2008;295:E613-17
   PubMed Web of Science ®Google Scholar
• Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004;110:3687-92
   PubMed Web of Science ®Google Scholar
• ter Avest E, Abbink EJ, de Graaf J, et al. Effect of rosuvastatin on insulin sensitivity in patients with familial combined hyperlipidaemia. Eur J Clin Invest 2005;35:558-64
   PubMed Web of Science ®Google Scholar
• Koh KK, Quon MJ, Han SH, et al. Simvastatin improves flow-mediated dilation, but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Diabetes Care 2008;31:776-82
   PubMed Web of Science ®Google Scholar
• Matsuura F, Oku H, Koseki M, et al. Adiponectin accelerates reverse cholesterol transport by increasing high density lipoprotein assembly in the liver. Biochem Biophys Res Commun 2007;358:1091-5
   PubMed Web of Science ®Google Scholar
• Oku H, Matsuura F, Koseki M, et al. Adiponectin deficiency suppresses ABCA1 expression and ApoA-I synthesis in the liver. FEBS Lett 2007;581:5029-33
   PubMed Web of Science ®Google Scholar
• Lara-Castro C, Fu Y, Chung BH, et al. Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr Opin Lipidol 2007;18:263-70
   PubMed Web of Science ®Google Scholar
• Saiki A, Oyama T, Endo K, et al. Preheparin serum lipoprotein lipase mass might be a biomarker of metabolic syndrome. Diabetes Res Clin Pract 2007;76:93-101
   PubMed Web of Science ®Google Scholar
• Dallinga-Thie GM, Dullaart RP, van Tol A. Concerted actions of cholesteryl ester transfer protein and phospholipid transfer protein in type 2 diabetes: effects of apolipoproteins. Curr Opin Lipidol 2007;18:251-7
   PubMed Web of Science ®Google Scholar
• Dullaart RP, de Vries R, Dallinga-Thie GM, et al. Plasma cholesteryl ester transfer protein mass and phospholipid transfer protein activity are associated with leptin in type 2 diabetes mellitus. Biochim Biophys Acta 2007;1771:113-18
   PubMed Web of Science ®Google Scholar
• Hara K, Horikoshi M, Yamauchi T, et al. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 2006;29:1357-62
   PubMed Web of Science ®Google Scholar
• Tomas E, Tsao TS, Saha AK, et al. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci USA 2002;99:16309-13
   PubMed Web of Science ®Google Scholar
• Bluher M, Brennan AM, Kelesidis T, et al. Total and high-molecular weight adiponectin in relation to metabolic variables at baseline and in response to an exercise treatment program: comparative evaluation of three assays. Diabetes Care 2007;30:280-5
   PubMed Web of Science ®Google Scholar
• Swarbrick MM, Havel PJ. Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. Metab Syndr Relat Disord 2008;6:87-102
   PubMedGoogle Scholar